ArticleDrugs - real world outcomes2026
Residual Burden in Adalimumab-Treated Patients with Hidradenitis Suppurativa: An Observational Cohort Study Based on Insurance Claims in the USA.
Article in Drugs - real world outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHidradenitis suppurativa (HS), a chronic, inflammatory skin disease, causes significant morbidity. Until 2023, adalimumab was the only US-approved biologic for patients with moderate to severe HS.
aimThis study describes the clinical profile, treatment utilization, and residual disease burden in patients with HS initiating adalimumab in the USA.
methodsThis observational cohort study used data from the Merative MarketScan
resultsThe main cohort included 2367 adult patients (70.4% Commercial/Medicare-insured and 29.6% Medicaid-insured). Overall, 60.3% of patients discontinued adalimumab and 6.5% of patients switched from adalimumab to other biologics; the drug survival at 6 and 12 months was 68.4% and 48.0%, respectively. Discontinuation predictors (based on baseline characteristics) included female sex, younger age, Medicaid insurance, and undergoing excision surgery. Despite a decrease in HCRU events during adalimumab treatment, the need for interventions such as antibiotics and surgeries persisted. The COVID-19 cohort showed similar trends in adalimumab drug survival and HCRU.
conclusionWhile adalimumab improved certain outcomes in HS, residual burden and high discontinuation rates indicate the need for accessible and durable therapies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.